Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single High-dose L-AMB for HIV-associated Talaromycosis
NCT06926569Phase 3Not yet recruiting
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of amphotericin b in talaromycosis (2 arms). Primary endpoint: Proportion of participants who achieve clinical resolution at 14 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
amphotericin b
03
Conditions
talaromycosis
Beyond the preview
Go deeper on NCT06926569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926569.